Clinical trials: Stage 4 Cancer
Kidney Neoplasms
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC…
- Trial name
- CheckMate 7C9 (NCT04513522)
- Testing
- Nivolumab, Ipilimumab
- Where
- 11 sites in India
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cancer, Breast Cancer
An EORTC Study Updating the QLQ-BR23 to BR45
Female breast cancer is still the most frequent type of cancer in Europe with 21 per 100,000 women .The EORTC QLQ-BR23 was one of the first modules developed to be used in conjunction with the core questionnaire EORTC QLQ-C30 and…
- Trial name
- NCT04270123
- Testing
- EORTC QLQ-BR45 questionnaire
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Leeds
Breast Cancer Stage IV
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
The purpose of this research is to assess the safety profile and clinical benefit of Awar-Awar leaf active fraction as a complementary therapy in chemotherapy of stage IV breast cancer
- Trial name
- NCT05033925
- Testing
- FADA (active fraction of Ficus septica leaf) 800 mg/day, FADA (active fraction of Ficus septica leaf) 2000 mg/day
- Where
- Indonesia
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Gadjah Mada University
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lung Cancer
ERCC1 Targeted Trial
Lung cancer is the leading cause of cancer death in the UK, leading to 34 000 deaths each year (22% of cancer deaths). Non-small cell lung cancer (NSCLC) is the most common histology, accounting for approximately 80% of cases and…
- Trial name
- ET (NCT00801736)
- Testing
- Cisplatin, Paclitaxel
- Where
- United Kingdom
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- University College, London
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer.
- Conditions
- Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04406831
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nuvance Health
Prostate Cancer
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects
Study Design : A randomized, open-label, four-sequence, four-period, crossover, single dosing, phase 1 study
- Trial name
- NCT06014853
- Testing
- SOL-804-F, Zytiga
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bukwang Pharmaceutical
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01999881
- Testing
- exercise intervention, standard follow-up care, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00984919
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00899028
- Testing
- comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis
- Where
- 4 sites in United States
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Nivolumab (OpdivoTM, BMS), a human IgG-4 anti-PD-1 monoclonal antibody has demonstrated anti-tumor activity in patients with advanced melanoma.
- Trial name
- ipniv (NCT02941744)
- Testing
- nivolumab, ipilimumab
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Intrahepatic Cholangiocarcinoma
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
- Trial name
- NCT05930119
- Testing
- HMPL-453, Rabeprazole
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Colon Adenocarcinoma, Colorectal Adenocarcinoma
Family Communications After Genetic Testing
This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer.
- Conditions
- Colon Adenocarcinoma, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Stage I Colon Cancer AJCC v8
- Trial name
- NCT07143487
- Testing
- Biospecimen Collection, Genetic Testing, Communication Intervention
- Where
- 365 sites in United States, Puerto Rico
- Volunteers
- 4,186 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage IV Gastric Cancer With Metastasis, Hyperthermic Intraperitoneal Chemotherapy
Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis
The incidence rate of gastric cancer is high in Southeast Asia, so is the mortality rate.Due to the lack of specific performance, about 5%-20% of patients have found peritoneal metastases at the time of first diagnosis.At…
- Conditions
- Stage IV Gastric Cancer With Metastasis, Hyperthermic Intraperitoneal Chemotherapy, Exploratory Behavior
- Trial name
- NCT03604614
- Testing
- Hyperthermic Intraperitoneal Chemotherapy, Without Hyperthermic Intraperitoneal Chemotherapy
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
NSCLC Stage IV
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China.
- Trial name
- NCT04076228
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Kiang Wu Hospital